Guillermo A Morales

US Patent:

8557807, Oct 15, 2013

Filed:

Jan 23, 2009

Appl. No.:

12/735309

Inventors:

Guillermo A. Morales - Carmel IN, US
Kevin T. Weber - Carmel IN, US
Jessica M. Newblom - Indianapolis IN, US
Xiaodong Peng - Carmel IN, US
Jingdong Su - Westfield IN, US
Joseph R. Garlich - Westfield IN, US

Assignee:

Signal Rx Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 31/538
A61K 31/5377
C07D 265/30
C07D 265/36
C07D 413/02
C07D 413/14

US Classification:

5142305, 5142325, 5142328, 544 79, 544121, 544122, 544124, 544141, 544143, 544146, 544105

Abstract:

The invention, relates to compounds of formula I (or pharmaceutically acceptable salts thereof) as defined herein, pharmaceutical compositions thereof, and their use in manufactures and methods for modulating biological processes including inhibition of kinase activity such as P1-3 kinase.

US Patent:

20030087334, May 8, 2003

Filed:

Nov 19, 2002

Appl. No.:

10/300730

Inventors:

Barry Bunin - Santa Clara CA, US
Timothy Powers - Oakland CA, US
Guillermo Morales - Patterson CA, US
Stephan Schurer - Mountain View CA, US
Steve Muskal - Carlsbad CA, US
Oliver Saunders - Burlingame CA, US

Assignee:

Libraria, Inc.

International Classification:

C12P001/00

US Classification:

435/041000

Abstract:

Computational tools automatically suggest/generate diverse reaction sets for particular precursors, classes of precursors, or different reaction chemistries. This is accomplished by automatically generating a group of reaction chemistries for a particular precursor or class of precursors. Some of the reactions and/or products may be produced without reliance on reactions and products reported in available references.

US Patent:

20140073584, Mar 13, 2014

Filed:

Sep 30, 2013

Appl. No.:

14/041279

Inventors:

Guillermo A. Morales - Oro Valley AZ, US
Kevin Weber - Carmel IN, US
Jessica Newblom - Indianapolis IN, US
Joseph R. Garlich - Volcano HI, US

Assignee:

SIGNALRX PHARMACEUTICALS, INC. - San Diego CA

International Classification:

C07D 495/04
A61K 45/06
A61K 47/48
A61K 31/5377
A61K 31/538
C07F 5/02

US Classification:

514 193, 544146, 5142338, 544143, 544 73, 5142305, 544121, 544 69, 530330, 544141, 544131, 544 79, 5142325

Abstract:

The invention relates to compounds of formula I (or pharmaceutically acceptable salts thereof) as defined herein, pharmaceutical compositions thereof, and their use in manufactures and methods for modulating biological processes including inhibition of kinase activity such as PI-3 kinase.

US Patent:

20170334925, Nov 23, 2017

Filed:

Aug 9, 2017

Appl. No.:

15/672627

Inventors:

- San Diego CA, US
Guillermo A. Morales - Oro Valley AZ, US
Joseph R. Garlich - Volcano HI, US

Assignee:

SignalRx Pharmaceuticals, Inc. - San Diego CA

International Classification:

C07D 495/04
A61K 31/541
A61K 31/538
A61K 45/06
A61K 31/5377

Abstract:

The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infaction, atheroscleosis, Type 1 or 2 diabetes, obesity, inflammatory disease, or Myc-depenent disorder including by modulating biological processes by the inhibition of PI3 kinase and/or bromodomain protein binding to substrates comprising the administration of a compound(s) of Formula I-IX (or pharmaceutically acceptable salts thereof) as defined herein.

US Patent:

20170101418, Apr 13, 2017

Filed:

Oct 19, 2016

Appl. No.:

15/297293

Inventors:

- San Diego CA, US
Guillermo A. Morales - Oro Valley AZ, US
Joseph R. Garlich - Volcano HI, US

Assignee:

SignalRx Pharmaceuticals, Inc. - San Diego CA

International Classification:

C07D 495/04
A61K 31/541
A61K 31/538
A61K 31/5377
A61K 45/06

Abstract:

The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infection, atheroscleosis, Type 1 or 2 diabetes, obesity, inflammatory disease, or Myc-depenent disorder including by modulating biological processes by the inhibition of PI3 kinase and/or bromodomain protein binding to substrates comprising the administration of a compound(s) of Formula I-IX (or pharmaceutically acceptable salts thereof) as defined herein.

US Patent:

20150344494, Dec 3, 2015

Filed:

May 4, 2015

Appl. No.:

14/702822

Inventors:

- San Diego CA, US
Guillermo A. Morales - Oro Valley AZ, US
Joseph R. Garlich - Volcano HI, US

Assignee:

SIGNALRX PHARMACEUTICALS, INC. - San Diego CA

International Classification:

C07D 495/04
A61K 31/5377
A61K 31/541
A61K 45/06

Abstract:

The invention relates to methods of treating diseases including but not limited to, cancer non-cancer proliferative disease, sepsis, autoimmune disease, viral infaction, atheroscleosis, Type 1 or 2 diabetes, obesity, inflammatory disease, or Myc-depenent disorder including by modulating biological processes by the inhibition of PI3 kinase and/or bromodomain protein binding to substrates composing the administration of a compound(s) of Formula I-IX (or pharmaceutically acceptable salts thereof) as defined herein.